RT Journal Article
SR Electronic
A1 Sylvester, Bruce
T1 Mixed Results with Telmisartan in ACE-Intolerant Patients with Diabetes or High-Risk Vascular Disease
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 6
SP 16
OP 16
DO 10.1177/155989770800800607
UL http://mdc.sagepub.com/content/8/6/16.abstract
AB Telmisartan did not reduce the primary composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure in patients with diabetes or high-risk vascular disease who are unable to tolerate standard treatment with angiotensin-converting enzyme inhibitors, according to findings from the Telmisartan Randomized AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease [TRANSCEND; NCT00153101] Trial.